RPO LLC’s Fate Therapeutics FATE Stock Holding History

RPO LLC’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-14,222	Closed	-$23.5K	–	58
2024 Q4	$23.5K	Buy	+14,222	New	+$35.8K	0.02%	74
2024 Q1	–	Sell	-12,307	Closed	-$46K	–	63
2023 Q4	$46K	Buy	+12,307	New	+$29.1K	0.07%	80

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

RPO LLC's FATE Position: Q1 2025 in Review

RPO LLC sold out of Fate Therapeutics (FATE) in Q1 2025, closing a stake of 14,222 shares — an estimated $23.5K sold.

RPO LLC first reported a position in FATE in Q4 2023 and held it in 2 quarters. The position peaked at $46K in Q4 2023. 132 funds tracked by Wall St. Rank hold FATE as of Q1 2025.

RPO LLC reported no remaining Fate Therapeutics position as of Q1 2025 after selling out during the quarter.
RPO LLC sold 14,222 Fate Therapeutics shares in Q1 2025, an estimated $23.5K.
RPO LLC first reported a position in Fate Therapeutics in Q4 2023 and held it in 2 quarters.
RPO LLC's Fate Therapeutics position peaked at $46K in Q4 2023.
132 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2025.

Based on RPO LLC's 13F filing for Q1 2025, filed 13 May 2025.